Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

World's first device-based treatment for small abdominal aortic aneurysms based on revolutionary new treatment paradigm

Objective

The Angiolutions device is a first-of-its-kind device stopping the life-threatening progression of small abdominal aortic aneurysm (AAA) – a pathological dilation of the aorta.
Angiolutions’ award-winning & patent-protected solution leverages a fundamentally new understanding of AAA growth discovered by the founders at Stanford University. They showed that stiffness gradients between the compliant (healthy) aorta and the adjacent stiff (diseased) aneurysm serve as a motor for AAA growth.
Based on this principle & together with key physicians, we developed a minimally-invasive, non-active aortic implant (class III). The nitinol-based device is positioned adjacent to the aneurysm sack via simple, catheter-based implantation. It is specifically designed to focally increase aortic stiffness in the compliant AAA neck region, thereby reducing stiffness gradients towards the stiff AAA sack that drive aneurysm growth.Hereby we achieve a fast, low-risk, size-stabilizing treatment of small AAA.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01

See all projects funded under this call

Coordinator

ANGIOLUTIONS GMBH
Net EU contribution
€ 2 499 999,00
Address
VAHRENWALDER STR 269A
30179 HANNOVER
Germany
SME
Yes
Region
Niedersachsen Hannover Region Hannover
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 999 673,50